Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer

Open Access
Publisher Website
Google Scholar
Abstract
To examine the mechanism of resistance to 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) in lung cancer, we continuously exposed the non‐small‐cell lung cancer (NSCLC) cell line NCI‐H23 to SN‐38 and selected the SN‐38‐resistant clone H23/SN‐38. After 2 months of culturing in SN‐38‐free conditions, H23/SN‐38 cells recovered their sensitivity to SN‐38 and were subsequently established as the revertant H23/SN‐38REV cell line. Because H23/SN‐38 cells show cross resistance to certain anticancer drugs, such as topotecan, etoposide, doxorubicin and mitoxantrone, we examined the gene and protein expression levels of drug efflux transporters of the ATP‐binding cassette (ABC) family. We found that both gene and protein expression of ABCG2/BCRP (ABCG2) in H23/SN‐38 cells was increased compared with that in NCI‐H23 cells and H23/SN‐38REV cells. The cellular accumulation of topotecan in H23/SN‐38 cells was decreased compared with that in NCI‐H23 and H23/SN‐38REV cells, and treatment with reserpine (an inhibitor of ABCG2) increased the cellular accumulation of topotecan in H23/SN‐38 cells. Furthermore, treatment with reserpine also altered the sensitivity of H23/SN‐38 cells to SN‐38. These results indicate that the upregulation of ABCG2 was functional, and related to the resistance of H23/SN‐38 cells to SN‐38. Moreover, we found that gene expression levels of ABCG2 were significantly correlated with the concentration of SN‐38 for 50% cell survival in 13 NSCLC cells (r = 0.592, P < 0.05). The present results indicate that the induction of ABCG2 by SN‐38 does confer acquired resistance to CPT‐11/SN‐38, but the induction of ABCG2 and subsequent drug resistance are reversible. However, the expression level of ABCG2 may be a useful indicator of CPT‐11/SN‐38 activity in lung cancer. (Cancer Sci 2006; 97: 192–198)

This publication has 19 references indexed in Scilit: